Dear ladies and gentlemen, welcome to the conference call of Biofrontera AG. At our customer's request, this conference will be recorded. As a reminder, all participants will be in a listen only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions] I now hand you over to Anke zur Mühlen, who will lead you for this conference. Please go ahead. Anke zur Mühlen: Welcome to Biofrontera's Conference Call on the Publication of our Annual Report 2021. On Saturday, we issued a press release on the financial results for the fiscal year 2021. We would like to remind you that in today's conference call, we will only provide a summary of the results. The annual report and the press release are available in the Investors section of our website. We encourage you to read the documents in their entirety. We caution the audience that Biofrontera's management will make forward-looking statements during this conference call. Actual results could differ materially from those expressed or implied by such forward-looking statements due to the risks and uncertainties associated with the Company's business. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 2, 2022. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I would now like to turn over to our CFO, Mr. Ludwig Lutter.

Thank you, Anke, very much. And thank you, dear shareholders, for taking the time today to participate in our fiscal 2021 earnings conference call. I'd like to start with a summary of Biofrontera's business, on our sales and clinical developments. I've now been a member of the Management Board at Biofrontera for just over a year and a number of changes in the structure of Biofrontera AG particularly in the last financial year. The successful IPO of Biofrontera Inc., our former 100% subsidiary, was a major and successful milestone in our corporate history. Biofrontera Inc. is now in an excellent position to leverage the potential of [Audio Gap] by further enhancing its investments in its sales activities. German Biofrontera companies will benefit directly from this growth through the existing license and supply agreement and can now focus directly on the European business. As we already announced in our forecast for the current financial year, this brings our company a big step closer to breakeven. Now back to the beginning of last year. After we started in 2021, with a successful capital increase that generated proceeds of gross €24.7 million for our company, a licensing agreement for the marketing of Ameluz was concluded with Medac GmbH for Poland in July. [indiscernible] Poland are expected to commence this year now that intensive work on the reimbursability of Poland has been underway for quite some time. In the fourth quarter of 2021, operational success then came one after another. As already mentioned, we were able to successfully IPO our U.S. subsidiary, Biofrontera Inc., on the U.S. Stock Exchange NASDAQ. We had decided to take the step because we were no longer able to ensure the financing of the dynamic development of Biofrontera Inc. due to the growth-inhibiting restrictions of the German corporate law.…

Dear, ladies and gentlemen, we will be back in a minute. Thank you for your patience. Dear, ladies and gentlemen, thank you for your patience. We're now back on.

Yes, apologies. Obviously, some technical issues here, and let me just continue where I dropped off. After our lawsuits between Deutsche Balaton Group and Biofrontera were settled at the -- as part of the mediation agreement, the Deutsche Balaton Group filed a declaratory lawsuit with the Cologne Regional Court on December 13, 2021, the day before the Annual General Meeting, of which the Company only learned by court service on February 9, 2022. The content of the lawsuit is again the legal investigation and determination of the so-called unwritten competence of the General Shareholder Meeting. In addition, Maruho Deutschland GmbH informed us in April that it intends to file a lawsuit against the capital measure resolutions passed at the Extraordinary General Meeting beginning of April. After this exciting year, I would like to express my warmest thanks to our employees, our supervisory board and you, dear shareholders, for your commitment to our company. Thank you very much. With that, I'd like to now open the lines for any questions.

[Operator Instructions] We have a first question. It's from Bruce Jackson of The Benchmark Company. The line is now open for you.

With regard to the market conditions in Germany and Spain, can you tell us a little bit about the impact of COVID-19 and whether or not it's had any impact on patient access to the physician offices?

Sure, Bruce. Happy to do so. Thanks for your question. Yes, we still feel it. Our sales teams are still reporting that it's not quite back to normal yet. We've seen some pretty nice performance, though, in Spain. It's growing nicely. Nevertheless, we still see, my gut feeling or what I hear back from the field, is there was still something around 20% or so, again, gut feeling, below what we could be without the pandemic.

And then with regard to Maruho, they've got a number of projects that are ongoing with you. Do you have any update on any of those projects, for example, the Asia-Pacific distribution agreement or any of the other development projects?

Nothing significant or nothing really timely yet. They're working on it. They're working on the approvals, Maruho is, and they are doing so with the speed that -- as quickly as possible. Nevertheless, we do not expect any revenues from Asia Pac this year or next year. We're more looking into the time range of '24, '25.

All right. That's it for me.

Thank you, Bruce.

[Operator Instructions] There are no further questions, and so I hand back to you.

Yes. Thank you very much for taking the time to listening to our call and much appreciate it. And we're looking forward to speaking to you soon again with some good news. Thank you.

Ladies and gentlemen, thank you for your attendance.